The DOI matches its Crossref record; 38 of the 38 references it cites were found in a registry or an index.
Enhancing Tumor-Specific Uptake of the Anticancer Drug Cisplatin with a Copper Chelator
Open accessAbstract
SUMMARY Uptake of the anticancer drug cisplatin is mediated by the copper transporter Ctr1 in cultured cells. Here we show in human ovarian tumors that low levels of Ctr1 mRNA are associated with poor clinical response to platinum-based therapy. Using a mouse model of human cervical cancer, we demonstrate that combined treatment with a copper chelator and cisplatin increases cisplatin-DNA adduct levels in cancerous but not in normal tissues, impairs angiogenesis, and improves therapeutic efficacy. The copper chelator also enhances the killing of cultured human cervical and ovarian cancer cells with cisplatin. Our results identify the copper transporter as a therapeutic target, which can be manipulated with copper chelating drugs to selectively enhance the benefits of platinum-containing chemotherapeutic agents.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Structure, Recognition, and Processing of Cisplatin−DNA Adducts
Jamieson, E. R., & Lippard, S. J. (1999) · Chemical Reviews · doi:10.1021/cr980421n · Cited by 2,949
Ozols, R. F., Bundy, B. N., Greer, B. E., Fowler, J. M., Clarke-Pearson, D., Burger, R. A., Mannel, R. S., DeGeest, K., Hartenbach, E. M., & Baergen, R. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.02.153 · Cited by 2,032
The Wilson disease gene is a putative copper transporting P–type ATPase similar to the Menkes gene
Bull, P. C., Thomas, G. R., Rommens, J. M., Forbes, J. R., & Cox, D. W. (1993) · Nature Genetics · doi:10.1038/ng1293-327 · Cited by 1,948
Cisplatin nephrotoxicity: Mechanisms and renoprotective strategies
Pabla, N., & Dong, Z. (2008) · Kidney International · doi:10.1038/sj.ki.5002786 · Cited by 1,918
Mechanisms for copper acquisition, distribution and regulation
Kim, B.-E., Nevitt, T., & Thiele, D. J. (2008) · Nature Chemical Biology · doi:10.1038/nchembio.72 · Cited by 1,588
The Wilson disease gene is a copper transporting ATPase with homology to the Menkes disease gene
Tanzi, R. E., Petrukhin, K., Chernov, I., Pellequer, J. L., Wasco, W., Ross, B., Romano, D. M., Parano, E., Pavone, L., Brzustowicz, L. M., et al. (1993) · Nature Genetics · doi:10.1038/ng1293-344 · Cited by 1,375
du Bois, A. (2003) · CancerSpectrum Knowledge Environment · doi:10.1093/jnci/djg036 · Cited by 1,113
Fogh, J., & Trempe, G. (1975) · Human Tumor Cells in Vitro · doi:10.1007/978-1-4757-1647-4_5 · Cited by 1,005
Uptake of the anticancer drug cisplatin mediated by the copper transporter Ctr1 in yeast and mammals
Ishida, S., Lee, J., Thiele, D. J., & Herskowitz, I. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.162491399 · Cited by 927
Self-citation(1975) · Springer eBooks · doi:10.1007/978-1-4757-1647-4 · Cited by 756
Natural history and epidemiology of HPV infection and cervical cancer
Castellsagué, X. (2008) · Gynecologic Oncology · doi:10.1016/j.ygyno.2008.07.045 · Cited by 590
Cellular genes analogous to retroviral onc genes are transcribed in human tumour cells
Eva, A., Robbins, K. C., Andersen, P. R., Srinivasan, A., Tronick, S. R., Reddy, E. P., Ellmore, N. W., Galen, A. T., Lautenberger, J. A., Papas, T. S., et al. (1982) · Nature · doi:10.1038/295116a0 · Cited by 497
The Role of Cellular Accumulation in Determining Sensitivity to Platinum-Based Chemotherapy
Hall, M. D., Okabe, M., Shen, D.-W., Liang, X.-J., & Gottesman, M. M. (2008) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.48.080907.180426 · Cited by 474
Copper-stimulated Endocytosis and Degradation of the Human Copper Transporter, hCtr1
Petris, M. J., Smith, K., Lee, J., & Thiele, D. J. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m209455200 · Cited by 345
Copper-transporting P-type adenosine triphosphatase (ATP7B) is associated with cisplatin resistance.
Komatsu, M., Sumizawa, T., Mutoh, M., Chen, Z., Terada, K., Furukawa, T., Yang, X., Gao, H., Miura, N., Sugiyama, T., et al. (2000) · PubMed · Cited by 328
Nose, Y., Kim, B.-E., & Thiele, D. J. (2006) · Cell Metabolism · doi:10.1016/j.cmet.2006.08.009 · Cited by 325
Holzer, A. K., Manorek, G. H., & Howell, S. B. (2006) · Molecular Pharmacology · doi:10.1124/mol.106.022624 · Cited by 322
Arbeit, J. M., Howley, P. M., & Hanahan, D. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.7.2930 · Cited by 304
Self-citationCharacterization of Mouse Embryonic Cells Deficient in the Ctr1 High Affinity Copper Transporter
Lee, J., Petris, M. J., & Thiele, D. J. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m208002200 · Cited by 244
Copper Transport Protein (Ctr1) Levels in Mice Are Tissue Specific and Dependent on Copper Status
Kuo, Y.-M., Gybina, A. A., Pyatskowit, J. W., Gitschier, J., & Prohaska, J. R. (2006) · The Journal of Nutrition · doi:10.1093/jn/136.1.21 · Cited by 218
Ooi, C. E., Rabinovich, E., Dancis, A., Bonifacino, J. S., & Klausner, R. D. (1996) · The EMBO Journal · doi:10.1002/j.1460-2075.1996.tb00720.x · Cited by 216
Genetic predisposition and parameters of malignant progression in K14-HPV16 transgenic mice.
Coussens, L. M., Hanahan, D., & Arbeit, J. M. (1996) · Europe PMC (PubMed Central) · Cited by 206
Self-citationFriedl, F., Kimura, I., Osato, T., & Ito, Y. (1970) · Experimental Biology and Medicine · doi:10.3181/00379727-135-35091a · Cited by 204
Treatment of metastatic malignant melanoma
Atallah, E., & Flaherty, L. (2005) · Current Treatment Options in Oncology · doi:10.1007/s11864-005-0002-5 · Cited by 192
Sensitivity of the cervical transformation zone to estrogen-induced squamous carcinogenesis.
Elson, D. A., Riley, R. R., Lacey, A., Thórdarson, G., Talamantes, F. J., & Arbeit, J. M. (2000) · PubMed · Cited by 187
Samimi, G., Katano, K., Holzer, A. K., Safaei, R., & Howell, S. B. (2004) · Molecular Pharmacology · doi:10.1124/mol.66.1.25 · Cited by 158
Distinct Mechanisms for Ctr1-mediated Copper and Cisplatin Transport
Sinani, D., Adle, D. J., Kim, H., & Lee, J. (2007) · Journal of Biological Chemistry · doi:10.1074/jbc.m703973200 · Cited by 129
Phase I Study of Copper-Binding Agent ATN-224 in Patients with Advanced Solid Tumors
Lowndes, S. A., Adams, A., Timms, A., Fisher, N., Smythe, J., Watt, S. M., Joel, S., Doñate, F., Hayward, C., Reich, S. D., et al. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-0315 · Cited by 107
Platinum-containing regimens for metastatic breast cancer
Egger, S. J., Willson, M. L., Morgan, J. L., Walker, H. S., Carrick, S. E., Ghersi, D., & Wilcken, N. (2017) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd003374.pub4 · Cited by 81
Oh, W. K., Tay, M. H., & Huang, J. (2006) · Cancer · doi:10.1002/cncr.22439 · Cited by 70
The use of copper-lowering therapy with tetrathiomolybdate in medicine
Brewer, G. J. (2008) · Expert Opinion on Investigational Drugs · doi:10.1517/13543780802621859 · Cited by 63
Gallagher, D. J., Milowsky, M. I., & Bajorin, D. F. (2008) · Cancer · doi:10.1002/cncr.23692 · Cited by 63
Cancer Therapy With Tetrathiomolybdate: Antiangiogenesis by Lowering Body Copper—A Review
Brewer, G. J., & Merajver, S. D. (2002) · Integrative Cancer Therapies · doi:10.1177/1534735402238185 · Cited by 50
Chemotherapy for recurrent and metastatic cervical cancer
Xia, T., Hu, W., Ramirez, P. T., et al. (2008) · Gynecologic Oncology · doi:10.1016/j.ygyno.2008.04.024 · Cited by 47
Platinum containing regimens for metastatic breast cancer
Carrick, S. E., Ghersi, D., Wilcken, N., & Simes, J. R. (2004) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd003374.pub3 · Cited by 45
Optimal Duration of Chemotherapy in Advanced Non-Small Cell Lung Cancer
Lustberg, M. B., & Edelman, M. J. (2007) · Current Treatment Options in Oncology · doi:10.1007/s11864-007-0020-6 · Cited by 41
Chemotherapy for high-grade glioma
Stewart, L. A., Burdett, S., & Glioma Meta-analysis Trialists Group (GMT) (2002) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd003913 · Cited by 40
Role of platinum agents in the management of advanced pancreatic cancer
Saif, M. W., & Kim, R. (2007) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.8.16.2719 · Cited by 24
Cited by
Molecular mechanisms of cisplatin resistance
Galluzzi, L., Senovilla, L., Vitale, I., Michels, J., Martins, I., Kepp, O., Castedo, M., & Kroemer, G. (2012) · Oncogene · doi:10.1038/onc.2011.384 · Cited by 2,760
Advances in Copper Complexes as Anticancer Agents
Santini, C., Pellei, M., Gandin, V., Porchia, M., Tisato, F., & Marzano, C. (2014) · Chemical Reviews · doi:10.1021/cr400135x · Cited by 1,790
Connecting copper and cancer: from transition metal signalling to metalloplasia
Ge, E. J., Bush, A. I., Casini, A., Cobine, P. A., Cross, J. R., DeNicola, G. M., Dou, Q. P., Franz, K. J., Gohil, V. M., Gupta, S., et al. (2022) · Nature Reviews Cancer · doi:10.1038/s41568-021-00417-2 · Cited by 1,298
Targeting copper in cancer therapy: ‘Copper That Cancer’
Denoyer, D., Masaldan, S., La Fontaine, S., & Cater, M. A. (2015) · Metallomics · doi:10.1039/c5mt00149h · Cited by 806
Systems biology of cisplatin resistance: past, present and future
Galluzzi, L., Vitale, I., Michels, J., Brenner, C., Szabadkai, G., Harel-Bellan, A., Castedo, M., & Kroemer, G. (2014) · Cell Death & Disease · doi:10.1038/cddis.2013.428 · Cited by 782
Metadata
- Authors
- Ishida, S., McCormick, F., Smith-McCune, K., & Hanahan, D.
- Venue
- Cancer Cell
- Publisher
- Elsevier BV
- Published
- 2010-06
- Volume
- 17
- Issue
- 6
- Pages
- 574-583
- ISSN
- 1535-6108 (ISSN-L)
- OpenAlex
- W2016203478
- Cited by
- 288
- References
- 38
- FWCI
- 7.84
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.